Northrop Grumman Q3 Earnings Surpass Estimates, Revenues Increase Y/Y

Northrop Grumman reported Q3 2026 adjusted EPS of $7.89, beating the $7.22 consensus by 9.3%, while sales rose 6.7% year over year to $11.12B. Backlog reached $109.6B, including $16.4B in quarterly net awards, and the company raised 2026 adjusted EPS guidance to $29.35–$29.75 from $28.60–$29.10 while keeping revenue guidance at $43.75–$44.25B. Results included mixed segment margins and a decline in the overall operating margin to 11.4% from 11.9%.

Analysis

The earnings signal is better on forward profitability than on demand: higher EPS guidance alongside unchanged revenue guidance points to improved earnings conversion, but the release does not establish whether that improvement is repeatable. The key test is Q4 cash conversion against the full-year free-cash-flow range; nine-month progress alone does not prove the target is secured. Backlog supports multi-year visibility, not near-term margin or cash certainty, particularly where program ramp-ups, award funding and delivery schedules remain gating factors.

The quality of growth is mixed. Aeronautics’ stronger margins support the case that B-21/F-35 activity is scaling productively, while Defense Systems’ move toward more cost-type work dilutes margin despite volume growth. That mix matters: backlog can expand while incremental profitability disappoints. Continued Sentinel ramp execution is therefore a larger valuation catalyst than the headline award total. Restricted-program demand and solid-rocket-motor activity may also tighten specialized supplier capacity, creating delivery and cost risk across defense primes rather than an automatic sector-wide earnings benefit.

Near term, the raised EPS outlook is a positive relative signal, but the modest sales surprise and lower consolidated operating margin temper the upside. Over 1–3 months, monitor year-end cash conversion and program-level margin commentary; over 6–18 months, Sentinel execution and funded backlog conversion dominate. The contrarian risk is treating backlog growth as equivalent to high-quality, funded revenue. A sustained margin decline or a miss against the cash-flow outlook would invalidate the constructive read.

Key Decisions for Investors

• Bias modestly long NOC on weakness rather than chase the earnings reaction. The thesis is improved earnings conversion and program ramp execution; reduce or exit if management cuts its full-year adjusted free-cash-flow outlook or subsequent results show continued consolidated margin erosion.
• For relative-value exposure, consider a small long NOC versus a diversified defense-prime basket, not an outright sector bet. Keep risk limited ahead of LMT’s Oct. 22 and GD’s Oct. 30 reports; those results could reveal whether NOC’s execution is company-specific or sector-wide.
• Track Q4 cash generation, Sentinel schedule/cost commentary, and Defense Systems margins. Treat backlog as lower quality if awards are delayed in funding, deliveries slip, or incremental cost-type work continues to pressure segment profitability.